



PATENT APPLICATION  
File No: 02-22

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of : Penny J. Thompson, Paul O. Sheppard  
Serial No. : 10/680,755  
Group Art Unit : 1646  
Examiner : Chandra, G.  
Filed : October 7, 2003  
For : USES OF HUMAN ZVEN ANTAGONISTS  
Date Submitted : April 11, 2006

**INFORMATION DISCLOSURE STATEMENT**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the examination of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

In accordance with 37 C.F.R. 1.97, the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been conducted, nor shall it be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).

The references are listed in PTO form 1449 which is in accordance with the requirements of M.P.E.P. 609. Applicants believe that their invention as claimed is patentable over the references. It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

Pursuant to the provisions of M.P.E.P. §609, Applicants further request that a copy of the 1449 form(s), marked as being considered and initialed by the Examiner, be returned with the next Official Communication.

It is believed that no fee is due, as this Information Disclosure Statement is filed prior to the receipt of any Action on the merits. However, in the event that a fee is due, please charge any fee or credit any overpayment to Deposit Account No. 26-0290.


Respectfully submitted,



Robyn Adams  
Registration No. 44,495

FORM PTO 1449 (REV 2-32)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

File No. 02-22

Serial No.  
10/680,755

Applicant(s):  
Penny J. Thompson, Paul O. Sheppard

Filing Date:  
October 7, 2003

Group: 1646

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
A1		5,891,720	04/06/99	Moore et al.			
A2		6,756,479	06/29/04	Sheppard et al.			
A3		20020115610	08/22/02	Zhou et al.			
A4		20040162238	08/19/04	Thompson et al.			
		A5 20050214800	09/29/05	Sheppard et al.			
		A6 20050153322	07/14/05	Sheppard et al.			
		A7 6,485,938	11/26/02	Sheppard et al.			
		A8 6,828,425	12/07/04	Sheppard et al.			

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		A9 WO99/63088	12/09/99	PCT (pages 471 and 472; Figures 265 to 267)			
		A10 WO99/06550	02/11/99	PCT (pages 50, 51, 375 and 376)			

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)**

	A11		Fedi, et al., "Isolation and Characterizatin of the Human Dkk-1 Homologue, a Novel Inhibitor of Mammalian Wnt Signaling," <i>J. Biol. Chem.</i> 274(27):19465-19472, July 2, 1999.
		A12	Hsieh et al., "A new secreted protein that binds to Wnt proteins and inhibits their activities," <i>Nature</i> 398:431-436, April 1, 1999.
	A13		Jilek et al., "Murine Bv8 gene maps near a synteny breakpoint of mouse chromosome 6 and human 3p21," <i>Gene</i> 256:189-195, 2000.
		A14	Li et al., "Identification of Two Prokineticin cDNAs: Recombinant Proteins Potently Contract Gastrointestinal Smooth Muscle," <i>Molec. Pharmacol.</i> 59(4):692-698, April 2001.
	A15		Weschelberger et al., "The mammalian homologues of frog Bv8 are mainly expressed in spermatocytes," <i>FEBS Lett.</i> 462:177-181, 1999.
		A16	EMBL Database Accession No. AF182069, October 2, 2000.
	A17		EMBL Database Accession No. AF333024, May 5, 2001..

Examiner	Date considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 1449 (REV 2-32)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

File No. 02-22

Serial No.  
10/680,755

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant(s):  
Penny J. Thompson, Paul O. Sheppard

Filing Date:  
October 7, 2003

Group: 1646

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)**

		A18	EMBL Database Accession No. AF333025, May 5, 2001.
		A19	EMBL Database Accession No. AF182066, December 14, 1999.
		A20	International Search Report for application No. PCT/US00/31278
		A21	Schweitz et al., "MIT1, a black mamba toxin with a new and highly potent activity on intestinal contraction," <i>FEBS Lett</i> 461:183-188, 1999.
		A22	Boisbouvier et al., "A Structural Homologue of Colipase in Black Mamba Venom Revealed by NMR Floating Disulphide Bridge Analysis," <i>J. Mol. Biol.</i> 283:205-219, 1998.
		A23	Joubert et al., "The Amino Acid Sequence of Protein A from <i>Dendroaspis polylepis polylepis</i> (Black mamba) Venom," <i>Hoppe-Seyler's Z. Physiol. Chem.</i> Bd.361:1787-1794, December 1980.
		A24	Morrison et al., "Genetically Engineered Antibdy Molecules." <i>Advances in Immunology</i> 44:65-92, 1989.
		A25	Harlow and Lane, "Antibodies A Laboratory Manual," <i>Cold Spring Harbor Laboratory</i> , pages 76, 361, 476, 555 and 626, 1988.

Examiner	Date considered
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.